fluorouracil has been researched along with Cancer of Salivary Gland in 23 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The growth inhibitory effects of 5-fluorouracil (5-Fu) and the combination of 5-Fu and human leukocyte interferon (HuIFN-alpha) on the human salivary gland adenocarcinoma cell line HSG in culture were examined by measuring colony formation in the semi-solid agar medium and cell proliferation in the monolayer culture." | 7.67 | Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture. ( Hayashi, Y; Kobayashi, S; Nitta, T; Sato, M; Urata, M; Yanagawa, T; Yoshida, H; Yura, Y, 1984) |
| "Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen." | 7.67 | Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989) |
| "The growth inhibitory effects of 5-fluorouracil (5-Fu) and the combination of 5-Fu and human leukocyte interferon (HuIFN-alpha) on the human salivary gland adenocarcinoma cell line HSG in culture were examined by measuring colony formation in the semi-solid agar medium and cell proliferation in the monolayer culture." | 3.67 | Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture. ( Hayashi, Y; Kobayashi, S; Nitta, T; Sato, M; Urata, M; Yanagawa, T; Yoshida, H; Yura, Y, 1984) |
| "Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen." | 3.67 | Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989) |
| "Adenoid cystic carcinoma is a relatively rare tumour which arises in the parotid and submandibular salivary glands." | 2.68 | Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. ( A'Hern, RP; Archer, D; Breach, N; Constenla, DO; Gore, ME; Henk, JM; Hill, ME; Rhys-Evans, P, 1997) |
| "From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors." | 1.37 | Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. ( Blair, EA; Cohen, EE; Haraf, DJ; Pederson, AW; Portugal, L; Salama, JK; Seiwert, T; Stenson, KM; Villaflor, VM; Vokes, EE; Witt, ME, 2011) |
| "Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis." | 1.36 | Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. ( Kelly, RJ; Sharon, E; Szabo, E, 2010) |
| "We found that upon treatment of a human salivary gland cancer cell line (cl-1) with 5-FU, the NF-kappaB activity was suppressed in a time-dependent manner." | 1.31 | 5-Fluorouracil induces apoptosis through the suppression of NF-kappaB activity in human salivary gland cancer cells. ( Aota, K; Azuma, M; Hayashi, Y; Ishimaru, N; Motegi, K; Sato, M; Tamatani, T; Yamashita, T, 2000) |
| "Fifteen patients with squamous cell carcinoma arising in the gingiva (8), tongue (3), floor of the mouth (1), or maxillary sinus (3) were enrolled." | 1.30 | Intranodal injection of anticancer drugs into fixed cervical metastatic lymph nodes. ( Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K, 1997) |
| "Chemosensitivity of salivary gland and oral cancer cell lines to 14 antitumor drugs was tested using a tetrazolium-based colorimetric assay and the relative antitumor activity (RAA) of the drugs was compared." | 1.28 | Chemosensitivity of salivary gland and oral cancer cell lines. ( Chen, JY; Liu, B; Situ, ZQ; Wang, W; Wu, JZ, 1992) |
| "A total of 77 patients with cancer of the head and neck area were treated with five different drug combination regimens." | 1.26 | Combination chemotherapy of head and neck cancer. ( Byers, RM; Gard, DA; Goepfert, H; Guillamondegui, OM; Holoye, PY; Jesse, RH, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Yamanaka, S | 1 |
| Suzuki, S | 1 |
| Ito, H | 1 |
| Sivasundaram, K | 1 |
| Hanamura, I | 1 |
| Okubo, I | 1 |
| Yoshikawa, K | 1 |
| Ono, S | 1 |
| Takahara, T | 1 |
| Satou, A | 1 |
| Tsuzuki, T | 1 |
| Ueda, R | 1 |
| Ogawa, T | 1 |
| Fujimoto, Y | 1 |
| Wang, XF | 1 |
| Wu, DM | 1 |
| Li, BX | 1 |
| Lu, YJ | 1 |
| Yang, BF | 1 |
| Ross, PJ | 1 |
| Teoh, EM | 1 |
| A'hern, RP | 2 |
| Rhys-Evans, PH | 1 |
| Harrington, KJ | 1 |
| Nutting, CM | 1 |
| Gore, ME | 2 |
| Sharon, E | 1 |
| Kelly, RJ | 1 |
| Szabo, E | 1 |
| Pederson, AW | 1 |
| Salama, JK | 1 |
| Haraf, DJ | 1 |
| Witt, ME | 1 |
| Stenson, KM | 1 |
| Portugal, L | 1 |
| Seiwert, T | 1 |
| Villaflor, VM | 1 |
| Cohen, EE | 1 |
| Vokes, EE | 1 |
| Blair, EA | 1 |
| Cai, BL | 1 |
| Xu, XF | 1 |
| Fu, SM | 1 |
| Shen, LL | 1 |
| Zhang, J | 1 |
| Guan, SM | 1 |
| Wu, JZ | 2 |
| Rosenberg, L | 1 |
| Weissler, M | 1 |
| Hayes, DN | 1 |
| Shockley, W | 1 |
| Zanation, A | 1 |
| Rosenman, J | 1 |
| Chera, B | 1 |
| White, JD | 1 |
| Junor, EJ | 1 |
| McGarva, J | 1 |
| McManners, J | 1 |
| Holland, IS | 1 |
| Sato, M | 6 |
| Yoshida, H | 4 |
| Urata, M | 1 |
| Yanagawa, T | 1 |
| Yura, Y | 1 |
| Nitta, T | 1 |
| Kobayashi, S | 1 |
| Hayashi, Y | 2 |
| Jones, AS | 1 |
| Phillips, DE | 1 |
| Cook, JA | 1 |
| Helliwell, TR | 1 |
| Hill, ME | 1 |
| Constenla, DO | 1 |
| Henk, JM | 1 |
| Rhys-Evans, P | 1 |
| Breach, N | 1 |
| Archer, D | 1 |
| Osaki, T | 1 |
| Ueta, E | 1 |
| Yoneda, K | 1 |
| Yamamoto, T | 1 |
| Okamoto, M | 1 |
| Kasetani, H | 1 |
| Kaji, R | 1 |
| Goda, H | 1 |
| Ohe, G | 1 |
| Uchida, D | 2 |
| Kawamata, H | 2 |
| Omotehara, F | 2 |
| Miwa, Y | 1 |
| Hino, S | 2 |
| Begum, NM | 2 |
| Aota, K | 2 |
| Azuma, M | 2 |
| Yamashita, T | 2 |
| Tamatani, T | 2 |
| Motegi, K | 1 |
| Ishimaru, N | 1 |
| Hoque, MO | 1 |
| Nakashiro, KI | 1 |
| Shinagawa, Y | 1 |
| Fujimori, T | 1 |
| Holoye, PY | 1 |
| Byers, RM | 1 |
| Gard, DA | 1 |
| Goepfert, H | 1 |
| Guillamondegui, OM | 1 |
| Jesse, RH | 1 |
| Situ, ZQ | 1 |
| Chen, JY | 1 |
| Liu, B | 1 |
| Wang, W | 1 |
| Nielsen, LL | 1 |
| Gurnani, M | 1 |
| Tyler, RD | 1 |
| Airoldi, M | 1 |
| Pedani, F | 1 |
| Brando, V | 1 |
| Gabriele, P | 1 |
| Giordano, C | 1 |
| Venook, AP | 1 |
| Tseng, A | 1 |
| Meyers, FJ | 1 |
| Silverberg, I | 1 |
| Boles, R | 1 |
| Fu, KK | 1 |
| Jacobs, CD | 1 |
| Mayer, M | 1 |
| Colon, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study[NCT01192087] | Phase 1/Phase 2 | 49 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for fluorouracil and Cancer of Salivary Gland
| Article | Year |
|---|---|
A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; | 1993 |
Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; F | 1997 |
21 other studies available for fluorouracil and Cancer of Salivary Gland
| Article | Year |
|---|---|
Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens.
Topics: Biopsy; Carcinoma, Mucoepidermoid; Cell Line, Tumor; Cisplatin; DNA-Binding Proteins; Fluorouracil; | 2023 |
Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma.
Topics: Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Carcinoma, Adenoid Cystic; Cell Line, Tumo | 2009 |
Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2009 |
Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
Topics: Adenoma, Pleomorphic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2010 |
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; Fl | 2011 |
Nuclear translocation of MRP1 contributes to multidrug resistance of mucoepidermoid carcinoma.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cas | 2011 |
Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Female; Fl | 2012 |
Adenocarcinoma of the salivary gland? A chemo-sensitive disease.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Fluorouracil; | 2004 |
Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line; C | 1984 |
Intranodal injection of anticancer drugs into fixed cervical metastatic lymph nodes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro.
Topics: Adenocarcinoma; Animals; Antibodies; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplat | 1998 |
Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Division; Cell Survival; Chromatin; Cisplatin; | 2000 |
5-Fluorouracil induces apoptosis through the suppression of NF-kappaB activity in human salivary gland cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Division | 2000 |
5-Fluorouracil suppression of NF-KappaB is mediated by the inhibition of IKappab kinase activity in human salivary gland cancer cells.
Topics: Fluorouracil; Humans; Hydrolysis; I-kappa B Kinase; MAP Kinase Kinase Kinase 1; NF-kappa B; NF-kappa | 2001 |
Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Mo | 2001 |
Combination chemotherapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Bone Marrow; Carcinoma, Squamous Cell; Cy | 1978 |
Chemosensitivity of salivary gland and oral cancer cell lines.
Topics: Cantharidin; Doxorubicin; Fluorouracil; Humans; Methotrexate; Mouth Neoplasms; Salivary Gland Neopla | 1992 |
Evaluation of the wap-ras transgenic mouse as a model system for testing anticancer drugs.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Disease Models, Animal; Fluorouracil; Genes, ras; | 1992 |
Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, A | 1989 |
Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1987 |
[Chemotherapy by intra-arterial path in cancer of the "head and neck" region].
Topics: Antineoplastic Agents; Bleomycin; Facial Neoplasms; Fluorouracil; Head; Head and Neck Neoplasms; Hum | 1971 |